ABR vs ALEX

ABR exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score for definitive distress assessment. Despite a deep value appearance via a Price/Book of 0.64 and a Graham Number of $14.47—nearly double the current price of $7.74—the stock faces severe headwinds from declining revenue and earnings, high leverage, and an unsustainable dividend. Profitability margins are strong, but negative growth trends, a 184.81% payout ratio, and deteriorating fundamentals outweigh valuation appeal. Technical trend at 0/100 confirms strong bearish momentum.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Despite strong historical price performance and a high dividend yield, the company faces significant headwinds with declining revenue and earnings, poor liquidity ratios, and negative insider sentiment. Valuation metrics appear stretched relative to fundamentals, particularly with a forward P/E of 34.02 amid negative growth. The stock trades above both the Graham Number ($17.77) and intrinsic value estimate ($7.07), suggesting overvaluation absent a turnaround.